Adverum Competitors

Stocks . USA . 
Stock . Adverum Biotechnologies
ADVM Stock  USD 6.45  0.29  4.71%   
Adverum Biotechnologies competes with Uniqure NV, Rocket Pharmaceuticals, Rhythm Pharmaceuticals, Solid Biosciences, and MeiraGTx Holdings; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Adverum Biotechnologies competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Adverum Biotechnologies to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Adverum Biotechnologies Correlation with its peers.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Adverum Biotechnologies competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Adverum Biotechnologies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
2.926.459.98
Details
Intrinsic
Valuation
LowRealHigh
1.615.148.67
Details
Naive
Forecast
LowNextHigh
2.906.439.96
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
5.326.808.28
Details

Adverum Biotechnologies Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Adverum Biotechnologies and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Adverum and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Adverum Biotechnologies does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
MGTX
+ 0.82
QURE
ACRV
+ 0.78
ADAG
AVTE
+ 0.76
MGTX
SLDB
+ 0.75
RCKT
MGTX
+ 0.71
RYTM
RZLT
+ 0.65
QURE
  
High negative correlations   
MGTX
- 0.8
SLDB
AVTE
- 0.71
SLDB
MGTX
- 0.56
RCKT
AVTE
- 0.55
RCKT
SLDB
- 0.51
RYTM
SLDB
- 0.51
QURE

Risk-Adjusted Indicators

There is a big difference between Adverum Stock performing well and Adverum Biotechnologies Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Adverum Biotechnologies' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
QURE  4.01 (0.30) 0.02  0.05  4.54 
(4.57)
 11.07 
(6.29)
 36.04 
RCKT  2.88 (0.59) 0.00 (0.21) 0.00 
 0.00 
 6.59 
(5.67)
 21.07 
RYTM  2.36  0.26  0.12  0.25  2.41 
(2.65)
 6.15 
(4.76)
 17.61 
SLDB  3.55 (0.91) 0.00 (0.24) 0.00 
 0.00 
 7.44 
(8.66)
 24.49 
MGTX  2.74  0.60  0.22  0.44  2.52 
(3.14)
 6.75 
(5.68)
 21.07 
AVTE  2.45  0.45  0.18  0.57  2.04 
(3.35)
 5.58 
(3.86)
 19.11 
ADAG  4.44 (0.25) 0.00 (0.78) 0.00 
 0.00 
 8.13 
(9.52)
 37.93 
ACRV  2.87 (0.43) 0.00 (0.13) 0.00 
 0.00 
 7.66 
(7.65)
 22.84 
RZLT  2.78 (0.03) 0.01  0.09  3.11 
(3.21)
 6.80 
(5.54)
 30.01 
ANTX  1.86  0.19  0.06  0.34  1.86 
(3.09)
 3.73 
(3.42)
 28.03 
All Fundamental Data

Adverum Biotechnologies Competitive Analysis

The better you understand Adverum Biotechnologies competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Adverum Biotechnologies' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Adverum Biotechnologies' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ADVM QURE RCKT RYTM SLDB MGTX AVTE ADAG ACRV RZLT
 4.71 
 6.45 
Adverum
 0.50 
 6.02 
Uniqure
 0.64 
 14.20 
Rocket
 0.48 
 62.25 
Rhythm
 1.56 
 5.69 
Solid
 2.50 
 6.55 
MeiraGTx
 1.49 
 2.64 
Aerovate
 4.05 
 2.31 
Adagene
 2.31 
 7.52 
Acrivon
 4.18 
 4.99 
Rezolute
Market Volatility
(90 Days Market Risk)
Moderately volatile
Slightly risky
Not too volatile
Very steady
Moderately volatile
Somewhat reliable
Somewhat reliable
Dangerous
Somewhat reliable
Moderately volatile
Market Performance
(90 Days Performance)
Very Weak
Weak
Very Weak
Good
Very Weak
Good
Good
Very Weak
Very Weak
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Very High
Above Average
Low
Low
Very High
Below Average
Low
About Average
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Hold
Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Hold
Hold
Strong Hold
Strong Hold
Strong Hold
Strong Hold
Strong Buy
Buy
Strong Buy
Strong Hold
Current Ratio
8.03
10.84
13.41
5.59
7.85
1.55
40.85
3.1
N/A
61.78
Net Asset
173.01 M
831.69 M
566.34 M
332.75 M
164.94 M
326.74 M
127.42 M
115.73 M
138.26 M
132.74 M
Profit Margin
N/A
N/A
N/A
-2.3
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(112.6 M)
(253.1 M)
(236.62 M)
(168.46 M)
(93.43 M)
(57.05 M)
(81.31 M)
(14.95 M)
(59.85 M)
(68.42 M)
Operating Margin
-29.22
-17.77
N/A
-1.32
N/A
-162.8
N/A
-45.35
N/A
N/A
Current Valuation
48.17 M
(72.75 M)
1.08 B
3.39 B
87.74 M
458.57 M
(11.96 M)
27.38 M
50.7 M
171.36 M
Price To Book
0.89
5.28
3.9
328.36
1.4
5.17
0.95
1.81
1.19
2.45
Retained Earnings
(919.78 M)
(890.41 M)
(959.37 M)
(894.74 M)
(658.75 M)
(554.23 M)
(163.42 M)
(277.75 M)
(116.42 M)
(329.44 M)
Current Asset
260.99 M
209.49 M
N/A
N/A
N/A
15.48 M
N/A
N/A
N/A
N/A
Beta
1.01
0.9
1.09
2.09
1.93
1.25
1.0
0.58
N/A
1.19
Number Of Employees
121
480
268
226
88
387
51
174
58
59
Shares Outstanding
20.8 M
48.74 M
91.16 M
61.46 M
39.95 M
78.15 M
28.87 M
44.27 M
31.14 M
57.94 M
Cash Flow From Operations
(90.9 M)
(145.93 M)
(194.92 M)
(136.16 M)
(94.18 M)
(105.36 M)
(56.78 M)
(28.45 M)
(42.64 M)
(57.37 M)
Total Debt
75.04 M
138.41 M
25.04 M
1.26 M
26.27 M
89.26 M
675 K
22.31 M
4.64 M
2.23 M
Return On Equity
-0.76
-1.48
-0.59
-1.48
-0.66
-0.92
-0.82
-0.46
-0.38
-0.58
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.3
-0.17
-0.34
-0.46
-0.35
-0.37
-0.49
-0.2
-0.24
-0.34
Number Of Shares Shorted
1.6 M
3.35 M
11.9 M
8.36 M
1.48 M
1.66 M
1.89 M
1.51 K
1.11 M
1.08 M
Book Value Per Share
6.93
1.15
3.62
0.18
4.29
2.17
2.79
1.28
5.38
2.27
Current Liabilities
6.57 M
24.38 M
N/A
N/A
N/A
11.6 M
N/A
N/A
N/A
N/A
Total Asset
173.01 M
831.69 M
566.34 M
332.75 M
164.94 M
326.74 M
127.42 M
115.73 M
138.26 M
132.74 M
Debt To Equity
0.43
0.29
0.057
0.011
0.15
0.16
0.008
0.15
N/A
0.001
Short Ratio
9.27
4.2
14.81
27.3
4.98
4.86
1.11
0.33
15.38
3.16
Target Price
30.29
17.58
46.79
70.27
17.43
23.25
2.33
10.54
21.56
13.0
Shares Owned By Institutions
79.15
81.95
96.6
99.48
90.06
55.12
99.98
25.54
75.97
64.24
Market Capitalization
128.14 M
294.9 M
1.29 B
3.81 B
230.94 M
499.4 M
76.23 M
108.46 M
234.14 M
289.14 M
Price To Earning
-2.1
2.51
N/A
N/A
N/A
-1.93
0.64
N/A
N/A
N/A
Price To Earnings To Growth
N/A
N/A
0.03
0.75
N/A
-1.28
N/A
N/A
N/A
N/A
Price To Sales
128.14
10.32
N/A
33.83
3.65
61.49
N/A
125.36
N/A
N/A
Net Income
(117.17 M)
(308.48 M)
(245.59 M)
(184.68 M)
(96.02 M)
(84.03 M)
(75.52 M)
(18.95 M)
(60.39 M)
(68.46 M)
Earnings Per Share
-5.95
-4.95
-2.73
-4.32
-3.04
-1.2
-2.99
-0.72
-2.66
-1.27
Shares Owned By Insiders
11.67
9.23
3.4
0.52
0.81
24.24
0.018
10.65
22.38
13.74
Revenue
3.6 M
15.84 M
N/A
77.43 M
N/A
14.02 M
N/A
18.11 M
N/A
N/A
Working Capital
77.86 M
578.18 M
329.72 M
253.06 M
115.22 M
92.54 M
106.59 M
81.99 M
116.39 M
119.05 M
Cash And Equivalents
235.84 M
500.52 M
321.37 M
235.6 M
162.88 M
72.11 M
151.99 M
168.04 M
N/A
150.41 M
Cash Per Share
2.37
10.71
4.87
4.64
1.44
1.61
6.22
3.87
N/A
3.87
Gross Profit
(81.68 M)
(87.37 M)
N/A
21.5 M
13.62 M
15.92 M
N/A
10.18 M
N/A
N/A
Day Typical Price
6.37
6.02
14.24
62.41
5.74
6.52
2.65
2.32
7.48
4.91
Accumulation Distribution
0.0418
0.0502
0.0365
0.0298
0.0407
0.0363
0.0296
0.14
0.0636
0.0693
Market Facilitation Index
0.27
0.31
0.53
1.89
0.24
0.24
0.08
0.35
0.49
0.35
Daily Balance Of Power
1.074074
(0.1)
0.1698
0.1587
(0.38)
0.6667
(0.50)
0.2571
0.3469
0.5714
Period Momentum Indicator
0.29
(0.03)
0.09
0.3
(0.09)
0.16
(0.04)
0.09
0.17
0.2
Rate Of Daily Change
1.05
1.0
1.01
1.0
0.98
1.03
0.99
1.04
1.02
1.04
Day Median Price
6.33
6.02
14.26
62.5
5.77
6.5
2.66
2.33
7.46
4.88
Price Action Indicator
0.27
(0.01)
(0.01)
(0.1)
(0.12)
0.13
(0.04)
0.03
0.15
0.22
Coefficient Of Variation
(6,490)
2830.55
(1,057)
661.03
(768.04)
461.34
620.65
(2,992)
(1,974)
2907.86
Mean Deviation
2.66
4.01
2.88
2.36
3.55
2.74
2.45
4.44
2.87
2.78
Jensen Alpha
(0.24)
(0.30)
(0.59)
0.2598
(0.91)
0.6028
0.4517
(0.25)
(0.43)
(0.03)
Total Risk Alpha
(0.60)
(0.69)
(0.98)
(0.01)
(1.32)
0.2428
0.0278
(1.15)
(0.86)
(0.50)
Sortino Ratio
N/A
0.0177
N/A
0.1241
N/A
0.2241
0.1784
N/A
N/A
0.0059
Downside Variance
N/A
22.22
N/A
8.52
N/A
9.82
6.39
N/A
N/A
11.08
Standard Deviation
3.53
5.92
3.95
3.22
4.65
3.82
3.58
6.17
4.21
4.22
Kurtosis
0.213
4.58
2.08
1.57
0.7462
2.59
4.3
2.0
1.64
10.39
Potential Upside
5.04
11.07
6.59
6.15
7.44
6.75
5.58
8.13
7.66
6.8
Treynor Ratio
(0.04)
0.0461
(0.21)
0.2531
(0.24)
0.4388
0.5701
(0.78)
(0.13)
0.0934
Maximum Drawdown
16.06
36.04
21.07
17.61
24.49
21.07
19.11
37.93
22.84
30.01
Variance
12.44
34.99
15.57
10.39
21.62
14.59
12.8
38.08
17.74
17.77
Market Risk Adjusted Performance
(0.03)
0.0561
(0.20)
0.2631
(0.23)
0.4488
0.5801
(0.77)
(0.12)
0.1034
Risk Adjusted Performance
(0)
0.0358
(0.06)
0.1235
(0.09)
0.1741
0.1313
(0.02)
(0.03)
0.0345
Skewness
(0.34)
1.53
0.9556
0.6441
(0.04)
0.9844
1.57
(0.60)
(0.23)
2.19
Semi Deviation
N/A
4.54
N/A
2.41
N/A
2.52
2.04
N/A
N/A
3.11
Information Ratio
(0.05)
0.0141
(0.13)
0.1124
(0.16)
0.1839
0.1261
(0.05)
(0.08)
0.0047
Value At Risk
(6.81)
(6.29)
(5.67)
(4.76)
(8.66)
(5.68)
(3.86)
(9.52)
(7.65)
(5.54)
Expected Short fall
N/A
(4.57)
N/A
(2.65)
N/A
(3.14)
(3.35)
N/A
N/A
(3.21)
Downside Deviation
N/A
4.71
N/A
2.92
N/A
3.13
2.53
N/A
N/A
3.33
Semi Variance
N/A
20.65
N/A
5.79
N/A
6.33
4.18
N/A
N/A
9.67

Adverum Biotechnologies Competition Performance Charts

Five steps to successful analysis of Adverum Biotechnologies Competition

Adverum Biotechnologies' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Adverum Biotechnologies in relation to its competition. Adverum Biotechnologies' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Adverum Biotechnologies in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Adverum Biotechnologies' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Adverum Biotechnologies, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Adverum Biotechnologies position

In addition to having Adverum Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Software Thematic Idea Now

Software
Software Theme
Companies that develop and distribute software and software systems to individuals or business. The Software theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Software Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:
How To Invest In Adverum
Details
Is Adverum Stock a good investment?
Details
What is Adverum Biotechnologies' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Adverum Biotechnologies Correlation with its peers.
To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY